Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Jaguar Health, Inc.

< Previous 1 2 3 Next >
Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers JAGX
Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers JAGX
Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers JAGX
Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea
From Jaguar Health, Inc.
Via AccessWire
Topics Death
Tickers JAGX
Jaguar Health, Inc. Reports 2021 Second Quarter Financial Results
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers JAGX
Jaguar Health Announces Time Change for Friday, August 13th Investor Webcast to 8:00 AM Eastern Time
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health to Host Investor Webcast Friday, August 13th at 8:30 AM Eastern Time Regarding Q2 2021 Financials & Business Updates
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers JAGX
REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Interview with Lisa Conte to Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Announces that Innovators with Jane King Interview with Lisa Conte will Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Napo EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A. Announce Close of 8,830,000 Euro Dragon SPAC Financing
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Announces Completion of Investigator-Initiated Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, August 6, 2021 and Encourages All Shareholders to Vote
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers JAGX
Jaguar Health Set to Join Russell Microcap Index
From Jaguar Health, Inc.
Via AccessWire
Topics Derivatives
Tickers JAGX
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, July 9, 2021 and Encourages All Shareholders to Vote
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers JAGX
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
REMINDER: Innovators with Jane King Webcast Interview with Jaguar Health CEO Lisa Conte & Dragon SPAC Founding Sponsor Josh Mailman to Take Place Thursday, June 3, 2021 at 8:30 AM Eastern
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Napo EU S.p.A., Jaguar Health’s Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPAC
From Jaguar Health, Inc.
Via AccessWire
Topics Initial Public Offering
Tickers JAGX
Napo Pharmaceuticals, Jaguar Health’s Subsidiary, Bolsters Management Team with Appointment of Darlene Horton, M.D. as Chief Medical Officer
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
Jaguar Health, Inc. Reports 2021 First Quarter Financial Results
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers JAGX
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Jaguar Health, Inc.
Via AccessWire
Tickers JAGX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.